Manufacturing Agreement for CCL

RNS Number : 8653X

Advanced Oncotherapy PLC

25 November 2014

 



25 November 2014

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Manufacturing agreement for CCL "higher speed accelerators"

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed a manufacturing agreement with VDL ETG Projects to manufacture the CCL (Coupled Cavity Linac) Accelerating Structures, a key milestone in the development of the LIGHT proton therapy system.

At the recent investor day held at the Royal Society of Medicine, Advanced Oncotherapy laid out its development plan and supplier partnering strategy. Today's announcement is a key step on the road to completing the Company's Supplier Partnering Strategy: VDL ETG Projects has an in-depth experience and a track-record in building accelerating modules. The CCL structures or "higher speed accelerators" are an essential part of the LIGHT Accelerator. They consist of a series of cells which accelerate the protons from energies of 37.5 Mega-electron Volts (MeV) to energies that can be applied usefully to a clinical setting (70MeV to 230MeV): 70MeV is the minimum energy suited for superficial tumours such as ocular tumours; the maximum energy of 230MeV has been selected to allow treatment of a central tumour that would be located at the maximum distance from the ideal entry point even in an obese patient.

Sanjeev Pandya CEO of Advanced Oncotherapy commented: "Thanks to our existing agreements with Toshiba, ScandiNova and the ENEA institution and with this new agreement, our LIGHT Accelerator System has now all the building blocks in place such that protons can reach their full final energy of 230MeV, an energy that will enable to treat all radiosensitive tumours found in a typical clinical setting. VDL ETG Projects is extremely well regarded in the industry and have successfully worked on building accelerating cavities. I am confident that by working together with their highly experienced team and set up, we will be on track to deliver our first CCL unit at the beginning of next year."

Bob Rose, Global Manufacturing & Supply Chain Director of Advanced Oncotherapy said: "VDL ETG Projects' experience and capabilities in manufacturing high-precision parts will serve to rapidly accelerate the development of our CCL modules. The relationship affirms our focus in creating innovative products and commitment to delivering this revolutionary piece of technology into the market - we are delighted to have VDL on board."

Guustaaf Savenije CTO of VDL ETG commented: "I am very pleased to be working with Advanced Oncotherapy, and that the Company has chosen VDL ETG Projects as their partner to build the CCL Accelerating Structures. AVO's LIGHT System technology is highly innovative and really represents one of the most exciting developments in the industry."  

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)	Tel: [phone]
Antonio Bossi / David Coaten
Beaufort Securities (Joint Broker)	Tel: [phone]
Saif Janjua / Jon Levinson
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

About VDL ETG Projects

With head offices and manufacturing facilities in Eindhoven, VDL ETG Projects specialises in the (co)development of high precision parts, prototypes, sub-assemblies, modules and complete mass manufacturing equipment.  VDL ETG has capabilities in high precision manufacturing in interlocking domains of Medical, Science & Technology, Semiconductors to Solar & Energy.

VDL ETG & VDL ETG Projects are part of VDL Groep. VDL Groep, with its head office in Eindhoven (The Netherlands), is an international industrial company focused on the development, production and sales of semi-finished products, buses and coaches and other finished products and the assembly of cars. Since the founding in 1953 this family-owned company has grown to include 85 operating companies, spread over 19 countries with approximately 10,000 employees. The strength of VDL Groep lies in the mutual cooperation between the companies.

 

END

 

 

MSCUSABRSOAAUAA